Content deleted Content added
BaeyerDrewson (talk | contribs) No edit summary |
BaeyerDrewson (talk | contribs) No edit summary |
||
| Line 26: | Line 26: | ||
}} |
}} |
||
'''CB-13''' ('''SAB-378''')<ref>{{Cite doi|10.1124/jpet.110.169946}}</ref> is a [[cannabinoid]] drug, which acts as a potent [[agonist]] at both the [[Cannabinoid receptor type 1|CB<sub>1</sub>]] and [[Cannabinoid receptor type 2|CB<sub>2</sub>]] receptors, but has poor [[blood–brain barrier]] penetration, and so produces only peripheral effects at low doses, with symptoms of central effects such as [[catalepsy]] only appearing at much higher dose ranges. It has [[hyperalgesia|antihyperalgesic]] properties in animal studies,<ref> |
'''CB-13''' ('''SAB-378''')<ref>{{Cite doi|10.1124/jpet.110.169946}}</ref> is a [[cannabinoid]] drug, which acts as a potent [[agonist]] at both the [[Cannabinoid receptor type 1|CB<sub>1</sub>]] and [[Cannabinoid receptor type 2|CB<sub>2</sub>]] receptors, but has poor [[blood–brain barrier]] penetration, and so produces only peripheral effects at low doses, with symptoms of central effects such as [[catalepsy]] only appearing at much higher dose ranges. It has [[hyperalgesia|antihyperalgesic]] properties in animal studies,<ref>{{cite DOI|10.1021/jm070317a}}</ref> and has progressed to preliminary human trials.<ref name="pmid19144772">{{cite journal |author=Gardin A, Kucher K, Kiese B, Appel-Dingemanse S |title=Cannabinoid receptor agonist 13, a novel cannabinoid agonist: first in human pharmacokinetics and safety |journal=Drug Metabolism and Disposition: the Biological Fate of Chemicals |volume=37 |issue=4 |pages=827–33 |year=2009 |month=April |pmid=19144772 |doi=10.1124/dmd.108.024000 |url= |issn=}}</ref> |
||
==See also== |
==See also== |
||
Revision as of 01:28, 2 April 2013
 | |
| Identifiers | |
|---|---|
| |
| CAS Number | |
| PubChem CID | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C26H24O2 |
| Molar mass | 368.467 g/mol g·mol−1 |
| 3D model (JSmol) | |
| |
| (verify) | |
CB-13 (SAB-378)[1] is a cannabinoid drug, which acts as a potent agonist at both the CB1 and CB2 receptors, but has poor blood–brain barrier penetration, and so produces only peripheral effects at low doses, with symptoms of central effects such as catalepsy only appearing at much higher dose ranges. It has antihyperalgesic properties in animal studies,[2] and has progressed to preliminary human trials.[3]
See also
References
- ^ Attention: This template ({{cite doi}}) is deprecated. To cite the publication identified by doi:10.1124/jpet.110.169946, please use {{cite journal}} (if it was published in a bona fide academic journal, otherwise {{cite report}} with
|doi=10.1124/jpet.110.169946instead. - ^ Template:Cite DOI
- ^ Gardin A, Kucher K, Kiese B, Appel-Dingemanse S (2009). "Cannabinoid receptor agonist 13, a novel cannabinoid agonist: first in human pharmacokinetics and safety". Drug Metabolism and Disposition: the Biological Fate of Chemicals. 37 (4): 827–33. doi:10.1124/dmd.108.024000. PMID 19144772.
{{cite journal}}: Unknown parameter|month=ignored (help)CS1 maint: multiple names: authors list (link)